BRIEF-CSL Behring Announces First Patient Enrollment In Phase 3 Clinical Trial Of CSL112
March 23, 2018 at 10:57 AM EDT
* CSL BEHRING ANNOUNCES FIRST PATIENT ENROLLMENT IN PHASE 3 CLINICAL TRIAL OF CSL112 TO ASSESS REDUCTION OF EARLY RECURRENT CARDIOVASCULAR EVENTS IN HEART ATTACK SURVIVORS
